QTTB
Q32 Bio Inc.
NASDAQ · USHealthcareBiotechnology
$15.04-0.07%
Price as of Jul 20, 2026
QTTB financials
Q32 Bio Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $53.7M | $0.00 | -$6.7M | $6.7M |
| Cost of revenue | $391.0K | $487.0K | $499.0K | $2.6M |
| Gross profit | $53.3M | -$487.0K | -$6.7M | $6.7M |
| Operating expenses | $36.4M | $65.6M | $41.6M | $45.9M |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$39.2M |
| Net income | $29.8M | -$47.7M | -$53.7M | -$42.8M |
| EBITDA | $31.3M | -$45.3M | -$47.8M | -$38.9M |
| Basic EPS | $2.42 | $-5.12 | $-16.70 | $-13.42 |
| Diluted EPS | $2.42 | $-6.58 | $-16.70 | $-13.42 |
| Balance sheet | ||||
| Cash & equivalents | $48.3M | $78.0M | $25.6M | $43.9M |
| Total assets | $61.8M | $92.3M | $47.1M | $61.8M |
| Total liabilities | $19.8M | $86.7M | $230.0M | $192.5M |
| Stockholders’ equity | $42.0M | $5.7M | -$182.9M | $178.0M |
| Total debt | $15.3M | $18.9M | $50.8M | $44.7M |
| Net debt | -$33.0M | -$59.1M | $25.2M | $838.0K |
| Cash flow | ||||
| Operating cash flow | -$33.5M | -$67.7M | -$18.7M | -$11.0M |
| Capital expenditure | $0.00 | -$75.0K | -$5.0K | -$2.5M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$13.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |